{"id":"W2313134734","doi":"10.1097/01.cot.0000289678.00323.68","title":"ODAC Votes to Approve Erlotinib (Tarceva) for New Indication","year":2005,"lang":"en","type":"article","venue":"Oncology Times","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Gemcitabine; Medicine; Pancreatic cancer; Internal medicine; Oncology; Clinical trial; Cancer; EGFR inhibitors; Erlotinib Hydrochloride; Gefitinib; Epidermal growth factor receptor","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004872032,0.0001305674,0.0004965707,0.000177631,0.0000989426,0.000008354154,0.0001387813,0.0002582297,0.001187291],"category_scores_gemma":[0.0006101832,0.0001103836,0.00008258972,0.0001637062,0.0001109543,0.00005520077,0.00005206816,0.0001893002,0.001099646],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002695644,"about_ca_system_score_gemma":0.0009488818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003144409,"about_ca_topic_score_gemma":0.00005672397,"domain_scores_codex":[0.9987746,0.00005999523,0.0002834688,0.0003063642,0.0001725964,0.000402994],"domain_scores_gemma":[0.9985559,0.0006150116,0.00008342935,0.0002592433,0.0001204921,0.0003659515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001365819,0.0006416374,0.0500337,0.00005813815,0.0002418506,0.00001149605,0.001765412,0.000007927512,0.004641745,0.003847731,0.6031671,0.3342174],"study_design_scores_gemma":[0.003855061,0.003350119,0.03815567,0.00003013355,0.0002355461,0.0000607488,0.0001731211,0.001040574,0.001517303,0.001221534,0.950213,0.0001472097],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4553643,0.0006945505,0.01621317,0.2080006,0.0002914406,0.004724911,0.00002333136,0.0002437414,0.314444],"genre_scores_gemma":[0.3883559,0.00008932432,0.2576939,0.01058281,0.004005041,0.000726877,0.000159784,0.00006443798,0.3383219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3470458,"threshold_uncertainty_score":0.9997258,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04608061756976181,"score_gpt":0.4004743114778221,"score_spread":0.3543936939080603,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}